Lamivudine Milpharm

Lamivudine, the active ingredient in Lamivudine Milpharm, is a nucleoside reverse transcriptase inhibitor (NRTI) presented as a tablet for oral use. It is employed in the management of human immunodeficiency virus (HIV) infection and chronic hepatitis B virus infection in adult patients.

GNH USA supplies Lamivudine Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams across global markets, ensuring consistent quality and regulatory compliance for antiretroviral therapy programs worldwide and supporting treatment adherence initiatives.

Lamivudine is an antiretroviral nucleoside reverse transcriptase inhibitor used in specific viral infections. - Human Immunodeficiency Virus (HIV) infection: Reduces viral replication and improves immune function when combined with other antiretrovirals. - Chronic hepatitis B virus (HBV) infection: Suppresses HBV DNA synthesis, helping to control liver disease progression. - Prevention of mother‑to‑child transmission of HIV: Used in combination regimens to lower the risk of vertical transmission.

Lamivudine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea - Headache - Fatigue - Diarrhea - Insomnia - Rash

Serious or Rare Side Effects: - Lactic acidosis - Severe hepatotoxicity - Pancreatitis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Bone marrow suppression - Severe hypersensitivity reactions

When prescribing lamivudine, clinicians should consider several safety aspects. - Renal function: Assess baseline renal function and adjust dosing if required. - Hepatic impairment: Monitor liver enzymes in patients with existing liver disease. - Concomitant antiretrovirals: Review for potential additive toxicity. - Pregnancy: Evaluate risk‑benefit ratio as safety data are limited. - Adherence: Encourage strict adherence to prevent resistance development. - Store at ambient temperature: Keep below 25 °C in original packaging, protect from moisture and light.

Lamivudine may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Didanosine: Increased risk of pancreatitis. - Stavudine: Enhanced mitochondrial toxicity. - Co‑administration with other NRTIs may raise the risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Tenofovir or other nephrotoxic agents: Monitor renal function. - Alcohol: May exacerbate liver toxicity. - Live attenuated vaccines: Assess immune status before administration.